Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-055X
    Keywords: Schlüsselwörter„Small-volume-resuscitation“ ; hyperton-hyperonkotische Lösung ; Volumentherapie ; extrakorporale Zirkulation ; Hypovolämie ; Key words Small-volume-resuscitation ; Hypertonic-hyperoncotic solution ; Volume therapy ; Extracorporeal circulation ; Hypovolaemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Abstract Patients who have undergone cardiac surgery with use of extracorporeal circulation frequently reveal marked hypovolaemia in spite of a highly positive fluid balance. This is thought to be due to transient microvascular damage and extravascular fluid shift. Further volume replacement to achieve haemodynamic stability in the postoperative period may cause fluid overload and congestive heart failure. The present study was designed to investigate whether this fluid overload could be avoided by using a hypertonic-hyperoncotic solution (group I: HHL, 10% hydroxyethylstarch 200/0.5 in 7.2% saline) instead of two different standard colloid solutions (group II: HA, 5% albumin; group III: HES, 6% hydroxyethylstarch in 0.9% saline). Methods. Twenty-one patients meeting our criteria for hypovolaemia immediately after cardiac surgery were randomly assigned to three groups. Patients in group I received HHL in increments of 150 ml, while patients in group II and group III were given HA and HES respectively in increments of 500 ml until hypovolemia was corrected. Haemodynamic assessment was done using a pulmonary artery thermodilution catheter. Intra- and extravascular volumes, including extravascular lung water (EVLW), intrathoracic blood volume (ITBV), and total blood volume (TBV) were measured by the double indicator technique using lung water software (COLD-System, Pulsion, Munich, Germany). Results. Correction of hypovolaemia-related haemodynamic parameters and restoration of normal TBV were achieved by 236±80 ml of HHL (group I), 857±244 ml of HA (group II) and 1000±0 ml of HES (group III) respectively. TBV increased significantly in each group, compared to baseline values. EVLW did not change significantly in any group. We found that the volume-augmenting effect of HHL per millilitre infused solution was more than four times that of HA and HES, primarily as a result of increasing plasma osmolality due to an increase of plasma sodium levels. This pronounced effect on intravascular volume of HHL lasted for only 2 h following infusion, however, and did not lead to any unwanted side effects. In the period between 2 and 20 h after primary volume replacement, further fluid therapy with colloids and crystalloids, guided by clinical signs of hypovolaemia, was necessary in each group of patients. The overall fluid requirements for the first 20 h after operation did not differ among the three resuscitation regimens. Conclusion. We found that HHL is a safe and effective solution for acute correction of hypovolaemia after cardiac surgery. The advantages of a smaller initial volume load by HHL cannot be maintained for longer than 2 h.
    Notes: Zusammenfassung Die Auswirkung einer hyperton-hyperonkotischen Lösung (HHL) auf kardiozirkulatorische Parameter wurden in dieser Studie an 21 hypovolämischen Patienten nach kardiochirurgischen Eingriffen mit den Effekten zweier isoton-isoonkotischer Lösungen (HA, HÄS) verglichen. Insbesondere wollten wir prüfen, ob durch Gabe der HHL (10% HÄS 200/0,5 in 7,2% NaCl) in Form einer „small-volume-resuscitation“ eine Kreislaufstabilisierung mit geringerer Volumenbelastung als durch Gabe von HA (5% Humanalbumin) bzw. HÄS (6% HÄS 200/0,5 in 0,9% NaCl) erreicht werden kann. Die Hypovolämie ließ sich mit HHL in wesentlich geringerer Dosierung (236±80 ml) ausgleichen als durch HA bzw. HÄS (857±244 ml, bzw. 1000±0 ml), wie aus dem Verlauf hämodynamischer Parameter (Herzindex, rechts- und linksventrikulärer Füllungsdruck) und der intravasalen Volumina (totales zirkulierendes Blutvolumen, intrathorakales Blutvolumen) hervorging. Diese größere Volumenwirksamkeit der HHL gegenüber HA und HÄS war jedoch nur ca. 2 h lang nachzuweisen. Über den gesamten Beobachtungszeitraum von 20 h ließ sich kein volumensparender Effekt der HHL feststellen. Für die akute Therapie einer hypovolämischen Kreislaufsituation stellt die HHL jedoch eine sichere und effektive Alternative zu anderen kolloidalen Volumenersatzmitteln dar.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Science Ltd
    Anaesthesia 55 (2000), S. 0 
    ISSN: 1365-2044
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Intensive care medicine 26 (2000), S. 733-739 
    ISSN: 1432-1238
    Keywords: Key words Hydroxyethyl starch ; Elimination ; Pharmacology ; Kidney ; Gut
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Objective: Hydroxyethyl starch (HES) is mainly eliminated via the kidneys. Any information about extrarenal elimination obtained so far has been either incomplete or contradictory. The objective of this study was to quantify the intestinal excretion of infused HES with a mean molecular weight of 200,000 and a molar substitution of 0.5 (HES 200/0.5) and to compare the reappearance/recovery rate in urine and plasma.¶Design: Prospective clinical study without control group.¶Setting: The study was conducted at the Institute of Hypertension of the Society of Clinical Pharmacology, Vienna, Austria, which is an establishment for research in volunteers.¶Participants: The results of six out of seven healthy male volunteers were appropriate for analysis. One trial subject had to be excluded from the study because of severe protocol violation (mixing of stool and urine samples).¶Interventions and methods: Each volunteer was administered 500 ml of 10 % HES 200/0.5 in a 0.9 % NaCl solution intravenously within 1 h. A gut lavage with 6 l of a polysaccharide free solution was continuously administered from 3 h prior to until 2 h after the HES infusion to facilitate the collection of the samples and to exclude any source of error at analysis. HES was quantified with the hexokinase method.¶Measurements and results: Right from the beginning of the infusion until 10 h after its completion, the cumulative HES excretion with feces (principle parameter) and urine as well as selective plasma volume and HES plasma level were measured. Six and 14 h after the infusion had been completed, the recovery rates of HES in urine were about 30 % and 40 %, respectively, and in plasma about 23 % and 8 %, respectively. By contrast, not more than a kind of “background noise amount” of HES (about 0.2 %) could be recovered in feces ( mean value in % of the infused amount of the substance). Six and 14 h after the infusion had been completed, the total recovery rates of HES were 53 % and 49 %, respectively.¶Conclusion: In a physiologically unimpaired gut HES 200/0.5 is not, or only to an infinitesimal extent, eliminated via the intestine. The question if there is any alternative path to renal excretion for HES still remains to be answered. As the calculated reappearance/recovery rate of HES is only about 50 % of the administered dose, further investigations as to the final fate of HES appear necessary.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Archives of dermatological research 285 (1993), S. 13-19 
    ISSN: 1432-069X
    Keywords: Hydroxyethylstarch ; Tissue storage ; Macrophages ; Immunohistochemistry ; Itching
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Severe itching for unknown reasons has been reported after administration of hydroxyethylstarch (HES) in haemodilution therapy of humans. After HES treatment, vacuoles in cells of various organs in humans have been shown, predominantly affecting the mononuclear phagocyte system. These vacuoles present indirect evidence for phagocytosis of HES particles. Since phagocytosis is also known to occur in the skin, this organ might represent a target for HES deposition, resulting in subsequent release of mediators responsible for the observed itching. The aim of the present investigation was to study skin biopsies of patients, who had received HES and suffered subsequently from itch. Skin sections were investigated for morphological impairment by means of light and electron microscopy, immunohistochemistry and immunoelectron microscopy using a polyclonal anti-HES antiserum. Storage of HES was demonstrated in the skin of all patients, mainly in dermal macrophages, endothelial cells of blood and lymph vessels, some perineural cells and endoneural macrophages of larger nerve fascicles, some keratinocytes and Langerhans cells. Treatment with antihistaminic agents proved ineffective in these patients; this fits with the observation that morphological signs of histamine release from mast cells were absent. These findings indicate that other mediators from HES-affected cells must be responsible for the development of the itching. Thus, investigation of HES storage may be a useful contribution to the elucidation of release of itch mediators and induction of pruritus.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...